Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

GCH1 mutations in hereditary spastic paraplegia

Parizad Varghaei, Grace Yoon, Mehrdad A Estiar, Simon Veyron, Etienne Leveille, Nicolas Dupre, Jean-François Trempe, Guy A Rouleau, Ziv Gan-Or
doi: https://doi.org/10.1101/2021.01.14.21249305
Parizad Varghaei
1Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada
2Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Yoon
3Divisions of Neurology and Clinical and Metabolic Genetics, Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mehrdad A Estiar
2Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada
4Department of Human Genetics, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Veyron
5Department of Pharmacology & Therapeutics and Centre de Recherche en Biologie Structurale - FRQS, McGill University, Montréal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etienne Leveille
6Faculty of Medicine, McGill University, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Dupre
7Axe Neurosciences, CHU de Québec-Université Laval, Québec, QC, Canada
8Department of Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-François Trempe
5Department of Pharmacology & Therapeutics and Centre de Recherche en Biologie Structurale - FRQS, McGill University, Montréal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy A Rouleau
2Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada
4Department of Human Genetics, McGill University, Montreal, Quebec, Canada
9Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: guy.rouleau@mcgill.ca ziv.gan-or@mcgill.ca
Ziv Gan-Or
2Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada
4Department of Human Genetics, McGill University, Montreal, Quebec, Canada
9Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: guy.rouleau@mcgill.ca ziv.gan-or@mcgill.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

GCH1 mutations have been associated with dopa-responsive dystonia (DRD), Parkinson’s disease (PD) and tetrahydrobiopterin (BH4)-deficient hyperphenylalaninemia B. Recently, GCH1 mutations have been reported in five patients with hereditary spastic paraplegia (HSP). Here, we analyzed a total of 400 HSP patients (291 families) from different centers across Canada by whole exome sequencing (WES). Three patients with heterozygous GCH1 variants were identified: monozygotic twins with a p.(Ser77_Leu82del) variant, and a patient with a p.(Val205Glu) variant. The former variant is predicted to be likely pathogenic and the latter is pathogenic. The three patients presented with childhood-onset lower limb spasticity, hyperreflexia and abnormal plantar responses. One of the patients had diurnal fluctuations, and none had parkinsonism or dystonia. Phenotypic differences between the monozygotic twins were observed, who responded well to levodopa treatment. Pathway enrichment analysis suggested that GCH1 shares processes and pathways with other HSP-associated genes, and structural analysis of the variants indicated a disruptive effect. In conclusion, GCH1 mutations may cause HSP; therefore, we suggest a levodopa trial in HSP patients and including GCH1 in the screening panels of HSP genes. Clinical differences between monozygotic twins suggest that environmental factors, epigenetics, and stochasticity could play a role in the clinical presentation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by CIHR Emerging Team Grant, in collaboration with the Canadian Organization for Rare Disorders (CORD), grant number RN127580 - 260005, and by a CIHR Foundation grant granted to GAR. MAE is funded by the Fonds de Recherche du Quebec-Sante (FRQS). SV holds a Basic Research Fellowship from Parkinson Canada. JFT holds a Canada Research Chair (Tier 2) in Structural Pharmacology. GAR holds a Canada Research Chair (Tier 1) in Genetics of the Nervous System and the Wilder Pen field Chair in Neurosciences. ZGO is supported by the Fonds de recherche du Quebec-Sante Chercheur-Boursier award and is a Parkinson Canada New Investigator awardee.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants have signed an informed consent form prior to enrollment, and the McGill University Health Center (MUHC) Research Ethics Board (REB) have approved the study protocols, REB number IRB00010120.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interests The authors declare no conflict of interests.

Data Availability

Data available on request from the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted March 07, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
GCH1 mutations in hereditary spastic paraplegia
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
GCH1 mutations in hereditary spastic paraplegia
Parizad Varghaei, Grace Yoon, Mehrdad A Estiar, Simon Veyron, Etienne Leveille, Nicolas Dupre, Jean-François Trempe, Guy A Rouleau, Ziv Gan-Or
medRxiv 2021.01.14.21249305; doi: https://doi.org/10.1101/2021.01.14.21249305
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
GCH1 mutations in hereditary spastic paraplegia
Parizad Varghaei, Grace Yoon, Mehrdad A Estiar, Simon Veyron, Etienne Leveille, Nicolas Dupre, Jean-François Trempe, Guy A Rouleau, Ziv Gan-Or
medRxiv 2021.01.14.21249305; doi: https://doi.org/10.1101/2021.01.14.21249305

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (943)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (419)
  • Epidemiology (8971)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1323)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (212)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10772)
  • Intensive Care and Critical Care Medicine (571)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (221)
  • Neurology (1819)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1892)
  • Public and Global Health (4111)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (364)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)